Ezetimibe/Simvastatin vs Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia: The VYTAL Study

87 Ezetimibe/Simvastatin 10/40mg Versus Atorvastatin 40mg in High Cardiovascular Risk Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Active-Controlled, Multicenter Study

“…Results of trials with placebo run-in were also consistent with the current study and this was true even in populations of metabolic syndrome subjects [13,20]. In one study of subjects with type 2 diabetes, numerically more subjects achieved LDL-C < 2.59 mmol/L with ezetimibe/ simvastatin 10/40 mg vs atorvastatin 40 mg; however, the difference was not significant between treatment groups (93.4% vs 89%, p < 0.07) [12].…”

“…Clinical trial results have demonstrated that combining ezetimibe with a statin more effectively lowers LDL-C vs. treatment with either of the individual components alone [7,8]. In addition, combining ezetimibe with simvastatin has been shown to provide greater cholesterol lowering vs. doubling the statin dose in patients with hypercholesterolemia [9], in those at high risk for coronary heart disease (CHD) [10], and in patients with either diabetes [11,12] or metabolic syndrome [13].…”

Ezetimibe: cholesterol lowering and beyond

“…When ezetimibe was added to ongoing, stable statin therapy in patients with metabolic syndrome, non-HDL-C was significantly reduced by -15.4 and -19.5% (p < 0.001) and in T2DM patients by -23.8 and -21.8% (p < 0.001) compared with statins alone across pooled doses [68,69]. In T2DM patients, the combination ezetimibe/simvastatin 10/20 mg provided significant additional reductions in non-HDL-C levels of -13.1 and -6.7% (p < 0.001 compared with atorvastatin 10 and 20 mg, respectively) and of -5.6% with ezetimibe 10/40 mg versus atorvastatin 40 mg (p < 0.001) [70].…”

“…Similarly, in T2DM patients, the ezetimibe/simvastatin combination tablet significantly lowers LDL-C from baseline compared with atorvastatin at all dose comparisons (-6.6 to -15.3%; p < 0.001) [70].…”

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

“…[30][31][32][33][34][35] In addition, several studies have previously demonstrated an enhanced ability of ezetimibe/statin therapy to facilitate the attainment of LDL-C goals relative to that seen with statin monotherapy. 34,36,37 The current analysis confirms these previous findings and extends them to include the enhanced ability of ezetimibe/statin versus statin monotherapy to facilitate optimal apoB and non-HDL-C levels in patients with and without diabetes.…”